JP2016529284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529284A5 JP2016529284A5 JP2016537829A JP2016537829A JP2016529284A5 JP 2016529284 A5 JP2016529284 A5 JP 2016529284A5 JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016529284 A5 JP2016529284 A5 JP 2016529284A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- formulation
- parp inhibitor
- cholesterol
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 claims 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- 238000009472 formulation Methods 0.000 claims 17
- 239000012661 PARP inhibitor Substances 0.000 claims 15
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 15
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 10
- 235000012000 cholesterol Nutrition 0.000 claims 10
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 9
- 239000002105 nanoparticle Substances 0.000 claims 8
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 4
- 229960000572 olaparib Drugs 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- AHIVQGOUBLVTCB-AWEZNQCLSA-N 2-[2-fluoro-4-[(2s)-pyrrolidin-2-yl]phenyl]-1h-benzimidazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C(C(=C1)F)=CC=C1[C@@H]1CCCN1 AHIVQGOUBLVTCB-AWEZNQCLSA-N 0.000 claims 1
- QIHBWVVVRYYYRO-ZDUSSCGKSA-N 3-(4-oxo-1h-quinazolin-2-yl)-n-[(1s)-1-phenylethyl]propanamide Chemical compound C1([C@@H](NC(=O)CCC=2NC(=O)C3=CC=CC=C3N=2)C)=CC=CC=C1 QIHBWVVVRYYYRO-ZDUSSCGKSA-N 0.000 claims 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims 1
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 claims 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 1
- JJWMRRNGWSITSQ-UHFFFAOYSA-N 5-phenacyloxy-2h-isoquinolin-1-one Chemical compound C=1C=CC(C(NC=C2)=O)=C2C=1OCC(=O)C1=CC=CC=C1 JJWMRRNGWSITSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012827 ATM inhibitor Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- SEKJSSBJKFLZIT-UHFFFAOYSA-N LSM-1988 Chemical compound C1=CC(CN(C)C)=CC=C1C1=NC2=CC=CC3=C2N1CCNC3=O SEKJSSBJKFLZIT-UHFFFAOYSA-N 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- RURAZZMDMNRXMI-UHFFFAOYSA-N PJ34 hydrochloride Chemical compound Cl.C1=CC=C2C3=CC(NC(=O)CN(C)C)=CC=C3NC(=O)C2=C1 RURAZZMDMNRXMI-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 230000000887 hydrating effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229950002133 iniparib Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870258P | 2013-08-27 | 2013-08-27 | |
| US61/870,258 | 2013-08-27 | ||
| PCT/US2014/053006 WO2015031536A1 (en) | 2013-08-27 | 2014-08-27 | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016529284A JP2016529284A (ja) | 2016-09-23 |
| JP2016529284A5 true JP2016529284A5 (cg-RX-API-DMAC7.html) | 2017-10-05 |
Family
ID=52587308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537829A Pending JP2016529284A (ja) | 2013-08-27 | 2014-08-27 | ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10111871B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3038600B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016529284A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015031536A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| AU2016281622C1 (en) * | 2015-06-25 | 2021-11-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US20170049775A1 (en) | 2015-08-21 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin |
| CN114099437A (zh) | 2015-10-16 | 2022-03-01 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
| EP3411027A1 (en) * | 2016-02-01 | 2018-12-12 | AbbVie Inc. | Extended release formulations of veliparib for the treatment of cancer |
| GB201608885D0 (en) * | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
| CN108201536A (zh) * | 2016-12-16 | 2018-06-26 | 中国科学院上海药物研究所 | 一种奥拉帕尼口服缓控释药物组合物及其用途 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| CN108201535A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种维利帕尼缓控释药物组合物及其用途 |
| EP3610859A4 (en) * | 2017-04-12 | 2021-01-27 | Beijing Inno Medicine Co., Ltd. | CERASOM DELIVERY SYSTEM FOR USE IN THE TARGETED ACTIVATION OF CD44 MOLECULES, MANUFACTURING METHOD FOR IT AND USE |
| WO2019200382A1 (en) * | 2018-04-13 | 2019-10-17 | The Board Of Regents Of University Of Texas System | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer |
| KR102017115B1 (ko) * | 2018-05-15 | 2019-09-02 | 충남대학교산학협력단 | 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| TW202112358A (zh) * | 2019-06-12 | 2021-04-01 | 美商里文Ｉｐ控股有限責任公司 | 用於改善癌症病患之成效的方法及組成物 |
| US11648211B2 (en) * | 2019-09-23 | 2023-05-16 | Northeastern University | Nanoencapsulated combination drug formulations |
| CN111187416A (zh) * | 2020-01-17 | 2020-05-22 | 广州古泉生物科技有限公司 | 一种壳聚糖-g-聚ε-己内酯衍生物载药纳米胶束的制备方法和应用 |
| WO2022115207A1 (en) * | 2020-11-25 | 2022-06-02 | Trustees Of Dartmouth College | Method for attenuating neuroinflammation |
| PL438742A1 (pl) * | 2021-08-14 | 2023-02-20 | Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością | Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną |
| EP4429636A1 (en) * | 2021-11-10 | 2024-09-18 | Crititech, Inc. | Rucaparib particles and uses thereof |
| WO2023191628A1 (en) | 2022-03-30 | 2023-10-05 | Bioneedle Drug Delivery B.V. | A process for storing biologically active constructs in a biodegradable material |
| CN116297044A (zh) * | 2022-12-07 | 2023-06-23 | 浙江萃泽医药科技有限公司 | 一种糠酸莫米松鼻喷雾剂中微晶纤维素粒径的测试方法 |
| WO2025024581A1 (en) * | 2023-07-24 | 2025-01-30 | University Of Maryland, College Park | Parp-inhibitor nanoparticles and methods thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3032004B2 (ja) | 1989-06-23 | 2000-04-10 | ザ リポソーム カンパニー，インコーポレイテッド | 標的化リポソーム及びリポソーム―蛋白質カップリング方法 |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NL9000207A (cg-RX-API-DMAC7.html) | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| JPH07509250A (ja) | 1992-07-27 | 1995-10-12 | アメリカ合衆国 | 血液脳バリヤーへのリポソームの標的化 |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| JP2001026544A (ja) | 1999-05-11 | 2001-01-30 | Sankyo Co Ltd | 脂溶性抗腫瘍薬のリポソーム製剤 |
| US7037520B2 (en) * | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| US20090220587A1 (en) | 2005-02-01 | 2009-09-03 | United State Army | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands |
| JP2010505880A (ja) * | 2006-10-06 | 2010-02-25 | ポリテクニック、インスティチュート、オブ、ニューヨーク、ユニバーシティー | ｐＨ感受性リポソーム組成物 |
| JP2010520855A (ja) | 2007-01-31 | 2010-06-17 | アフィーマックス・インコーポレイテッド | 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー |
| WO2008139804A1 (ja) * | 2007-05-14 | 2008-11-20 | Ltt Bio-Pharma Co., Ltd. | 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子 |
| KR100979462B1 (ko) | 2007-08-03 | 2010-09-02 | 한국화학연구원 | 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법 |
| US20110233079A1 (en) * | 2009-06-30 | 2011-09-29 | Macinnes Susan E | Medical Kit, Packaging System, Instruction Insert, and Associated Methods |
| TWI468188B (zh) | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| WO2009129387A2 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20100104629A1 (en) * | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20110123451A1 (en) | 2009-11-21 | 2011-05-26 | Max Kullberg | Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin |
| EP2533640B1 (en) | 2010-02-08 | 2016-09-28 | Medivation Technologies, Inc. | Processes of synthesizing dihydropyridophthalazinone derivatives |
| US9549901B2 (en) * | 2010-09-03 | 2017-01-24 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
-
2014
- 2014-08-27 EP EP14841089.7A patent/EP3038600B1/en active Active
- 2014-08-27 WO PCT/US2014/053006 patent/WO2015031536A1/en not_active Ceased
- 2014-08-27 US US14/914,932 patent/US10111871B2/en active Active
- 2014-08-27 JP JP2016537829A patent/JP2016529284A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529284A5 (cg-RX-API-DMAC7.html) | ||
| Masjedi et al. | An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications | |
| Hao et al. | Supramolecular chemotherapy: carboxylated pillar [6] arene for decreasing cytotoxicity of oxaliplatin to normal cells and improving its anticancer bioactivity against colorectal cancer | |
| Pereira et al. | Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity | |
| Tawfik et al. | Low-frequency versus high-frequency ultrasound-mediated transdermal delivery of agomelatine-loaded invasomes: development, optimization and in-vivo pharmacokinetic assessment | |
| Li et al. | Self-assembled nanoparticles based on amphiphilic anticancer drug–phospholipid complex for targeted drug delivery and intracellular dual-controlled release | |
| ES2762224T3 (es) | Liposomas que comprenden lípidos conjugados con polímero y usos relacionados | |
| CN108024960B (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| Bathara et al. | Exploring the promising potential of high permeation vesicle-mediated localized transdermal delivery of docetaxel in breast cancer to overcome the limitations of systemic chemotherapy | |
| JP2019501198A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532665A5 (cg-RX-API-DMAC7.html) | ||
| JP2015519330A5 (cg-RX-API-DMAC7.html) | ||
| CN109350600B (zh) | 设计脂质体水相和非水相部分的组成来控制药物的释放趋势 | |
| JP2015523355A5 (cg-RX-API-DMAC7.html) | ||
| Duong et al. | One step encapsulation of small molecule drugs in liposomes via electrospray-remote loading | |
| Gandhi et al. | Lipid-Based inhalable micro-and nanocarriers of active agents for treating non-small-cell lung cancer | |
| Ma et al. | Cancer cell targeting, controlled drug release and intracellular fate of biomimetic membrane-encapsulated drug-loaded nano-graphene oxide nanohybrids | |
| EP1393719A1 (en) | Camptothecin-carboxylate formulations | |
| Maddiboyina et al. | Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications | |
| Xu et al. | Lipid-coated CaCO3 nanoparticles as a versatile ph-responsive drug delivery platform to enable combined chemotherapy of breast cancer | |
| TR201818978T4 (tr) | İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler | |
| KR20210081256A (ko) | 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트 | |
| Abdelaziz et al. | Solid lipid nanoparticle-based drug delivery for lung cancer | |
| Hu et al. | Liposomes in drug delivery: status and advances | |
| Nayak et al. | Applications of nanovesicular drug delivery |